# Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery

> **NCT00025181** · PHASE1 · COMPLETED · sponsor: **University of Southern California** · enrollment: 19 (actual)

## Conditions studied

- Intraocular Melanoma
- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** MART-1 antigen
- **BIOLOGICAL:** gp100 antigen
- **BIOLOGICAL:** incomplete Freund's adjuvant
- **BIOLOGICAL:** ipilimumab
- **BIOLOGICAL:** tyrosinase peptide
- **PROCEDURE:** adjuvant therapy

## Key facts

- **NCT ID:** NCT00025181
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-10
- **Primary completion:** 2003-01
- **Final completion:** 2005-06
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2014-05-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00025181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00025181, "Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00025181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*